The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
Launched by AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY · Dec 5, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. Visual analysis of images: describe the location, size, shape and degree of uptake of lesions;
2. Semi-quantitative analysis: the ratio of lesion site uptake to liver uptake was measured by area of interest method (ROI);
3. Comparative analysis: Compared with clinical routine 18F-FDG PET/CT imaging, the advantages of PSMA PET/CT imaging were clarified;
4. Evaluation and analysis of efficacy: before and after treatment, to clarify the early treatment evaluation value of PSMA PET/CT imaging, and compare it with 18F-FDG PET/CT imaging;
5. Prognostic study: Through multi-factor analysis, the...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Prostate cancer is clinically suspected. The patient was diagnosed with prostate cancer by biopsy. Prostate cancer needs to be evaluated after treatment.
- Exclusion Criteria:
- • Patients who did not meet the requirements as assessed by the investigator.
About Affiliated Hospital Of Jiangnan University
The Affiliated Hospital of Jiangnan University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of experienced healthcare professionals to conduct rigorous studies aimed at improving patient outcomes. Committed to ethical standards and patient safety, the Affiliated Hospital of Jiangnan University plays a crucial role in translating clinical research into practical applications, fostering collaboration with academic institutions and industry partners to drive medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuxi, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported